Identification and optimization of PIKfyve inhibitors that can achieve results that are directly transferable to the market.
The project aims to identify effective drugs against the SARS-CoV-2 virus, which can act at the level of PIKfyve lipid kinase inhibition. A programme to optimize broad-spectrum antivirals has been proposed based on previously identified novel prototypes as virtual inhibitors of this kinase, and after experimentally validating their antiviral effect against SARS-CoV-2.
Principal Investigator: Carmen Gil (CIB)
